4.6 Article

Blockade of Fatty Acid Synthase Triggers Significant Apoptosis in Mantle Cell Lymphoma

Journal

PLOS ONE
Volume 7, Issue 4, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0033738

Keywords

-

Funding

  1. Canadian Institute of Health Research
  2. Alberta Cancer Foundation
  3. Canadian Cancer Society Research Institute

Ask authors/readers for more resources

Fatty acid synthase (FASN), a key player in the de novo synthetic pathway of long-chain fatty acids, has been shown to contribute to the tumorigenesis in various types of solid tumors. We here report that FASN is highly and consistently expressed in mantle cell lymphoma (MCL), an aggressive form of B-cell lymphoid malignancy. Specifically, the expression of FASN was detectable in all four MCL cell lines and 15 tumors examined. In contrast, benign lymphoid tissues and peripheral blood mononuclear cells from normal donors were negative. Treatment of MCL cell lines with orlistat, a FASN inhibitor, resulted in significant apoptosis. Knockdown of FASN expression using siRNA, which also significantly decreased the growth of MCL cells, led to a dramatic decrease in the cyclin D1 level. beta-catenin, which has been previously reported to be upregulated in a subset of MCL tumors, contributed to the high level of FASN in MCL cells, Interesting, siRNA knock-down of FASN in turn down-regulated beta-catenin. In conclusion, our data supports the concept that FASN contributes to the pathogenesis of MCL, by collaborating with beta-catenin. In view of its high and consistent expression in MCL, FASN inhibitors may hold promises for treating MCL.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Xenograft Models of Primary Acute Myeloid Leukemia for the Development of Imaging Strategies and Evaluation of Novel Targeted Therapies

Pascal Gelebart, Mihaela Popa, Emmet McCormack

CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2015)

Article Multidisciplinary Sciences

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Marcus J. G. W. Ladds, Ingeborg M. M. van Leeuwen, Catherine J. Drummond, Su Chu, Alan R. Healy, Gergana Popova, Andres Pastor Fernandez, Tanzina Mollick, Suhas Darekar, Saikiran K. Sedimbi, Marta Nekulova, Marijke C. C. Sachweh, Johanna Campbell, Maureen Higgins, Chloe Tuck, Mihaela Popa, Mireia Mayoral Safont, Pascal Gelebart, Zinayida Fandalyuk, Alastair M. Thompson, Richard Svensson, Anna-Lena Gustavsson, Lars Johansson, Katarina Farnegardh, Ulrika Yngve, Aljona Saleh, Martin Haraldsson, Agathe C. A. D'Hollander, Marcela Franco, Yan Zhao, Maria Hakansson, Bjorn Walse, Karin Larsson, Emma M. Peat, Vicent Pelechano, John Lunec, Borivoj Vojtesek, Mar Carmena, William C. Earnshaw, Anna R. McCarthy, Nicholas J. Westwood, Marie Arsenian-Henriksson, David P. Lane, Ravi Bhatia, Emmet McCormack, Sonia Lain

NATURE COMMUNICATIONS (2018)

Correction Multidisciplinary Sciences

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Marcus J. G. W. Ladds, Ingeborg M. M. van Leeuwen, Catherine J. Drummond, Su Chu, Alan R. Healy, Gergana Popova, Andres Pastor Fernandez, Tanzina Mollick, Suhas Darekar, Saikiran K. Sedimbi, Marta Nekulova, Marijke C. C. Sachweh, Johanna Campbell, Maureen Higgins, Chloe Tuck, Mihaela Popa, Mireia Mayoral Safont, Pascal Gelebart, Zinayida Fandalyuk, Alastair M. Thompson, Richard Svensson, Anna-Lena Gustavsson, Lars Johansson, Katarina Farnegardh, Ulrika Yngve, Aljona Saleh, Martin Haraldsson, Agathe C. A. D'Hollander, Marcela Franco, Yan Zhao, Maria Hakansson, Bjorn Walse, Karin Larsson, Emma M. Peat, Vicent Pelechano, John Lunec, Borivoj Vojtesek, Mar Carmena, William C. Earnshaw, Anna R. McCarthy, Nicholas J. Westwood, Marie Arsenian-Henriksson, David P. Lane, Ravi Bhatia, Emmet McCormack, Sonia Lain

NATURE COMMUNICATIONS (2018)

Article Hematology

Gene methylation and silencing of SOCS3 in mantle cell lymphoma

Ommoleila Molavi, Peng Wang, Zoulika Zak, Pascal Gelebart, Andrew Belch, Raymond Lai

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Article Cell Biology

The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma

Peng Wang, Jing Dong Zhang, Fang Wu, Xiaoxia Ye, David Sharon, Mary Hitt, Todd P. McMullen, Samar A. Hegazy, Pascal Gelebart, Jianchang Yang, Yupo Ma, Raymond Lai

CELLULAR SIGNALLING (2012)

Correction Cell Biology

Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma (vol 25, pg 295, 2013)

Samar A. Hegazy, Abdulraheem Alshareef, Pascal Gelebart, Mona Anand, Hanan Armanious, Robert J. Ingham, Raymond Lai

CELLULAR SIGNALLING (2013)

Article Cell Biology

Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma

Hanan Armanious, Pascal Gelebart, Mona Anand, Raymond Lai

CELLULAR SIGNALLING (2013)

Article Cell Biology

Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma

Samar A. Hegazy, Abdulraheem Alshareef, Pascal Gelebart, Mona Anand, Hanan Armanious, Robert J. Ingham, Raymond Lai

CELLULAR SIGNALLING (2013)

Article Oncology

Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer

Jingdong Zhang, Peng Wang, Mark Dykstra, Pascale Gelebart, David Williams, Robert Ingham, Esther Ekpe Adewuyi, Raymond Lai, Todd McMullen

JOURNAL OF PATHOLOGY (2012)

Article Biochemistry & Molecular Biology

Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma

Gregory Lazarian, Chloe Friedrich, Anne Quinquenel, Julie Tran, Souhail Ouriemmi, Elisabetta Dondi, Antoine Martin, Imane Mihoub, David Chiron, Celine Bellanger, Carole Fleury, Pascal Gelebart, Emmet McCormack, Dominique Ledoux, Catherine Thieblemont, Jacek Marzec, John G. Gribben, Florence Cymbalista, Nadine Varin-Blank, Laura Gardano, Fanny Baran-Marszak

ONCOGENE (2020)

Review Biochemistry & Molecular Biology

Endoplasmic Reticulum Calcium Pumps and Tumor Cell Differentiation

Bela Papp, Sophie Launay, Pascal Gelebart, Atousa Arbabian, Agnes Enyedi, Jean-Philippe Brouland, Edgardo D. Carosella, Homa Adle-Biassette

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Article Biochemistry & Molecular Biology

Gene Methylation and Silencing of WIF1 Is a Frequent Genetic Abnormality in Mantle Cell Lymphoma

Abdulraheem Alshareef, Anthea C. Peters, Pascal Gelebart, Will Chen, Raymond Lai

Summary: The constitutive activation of the Wnt canonical pathway (WCP) in mantle cell lymphoma (MCL) is mainly due to gene methylation/silencing of WIF1, which promotes cell growth. Gene transfection of WIF1 into cells significantly reduces cell growth and results in downregulation of various proteins in WCP.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Letter Hematology

Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line

Sahba Shafiee, Pascal Gelebart, Mihaela Popa, Monica Hellesoy, Randi Hovland, Rakel Brendsdal Forthun, Jungwoo Lee, Kaoru Tohyama, Anders Molven, Biju Parekkadan, Bjorn Tore Gjertsen, Astrid Olsnes Kittang, Emmet McCormack

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Article Hematology

Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells

Pascal Gelebart, May Eriksen Gjerstad, Susanne Benjaminsen, Jianhua Han, Ida Karlsen, Mireia Mayoral Safont, Calum Leitch, Zinayida Fandalyuk, Mihaela Popa, Lars Helgeland, Bela Papp, Fanny Baran-Marszak, Emmet McCormack

Summary: This study reports the identification and expression of a new AXL splice variant, AXL3, in MCL cells, which is constitutively activated and is essential for MCL cell survival. Inhibition of AXL3 leads to apoptosis of MCL cells and significantly reduces the activation of proproliferative and survival pathways. Bemcentinib shows promise as a targeted therapy for MCL, demonstrating higher efficacy than ibrutinib in reducing tumor burden and increasing overall survival in preclinical studies.

BLOOD (2023)

No Data Available